Although lipophilic statins are thought to readily cross the blood-brain barrier (Box 1) (Botti et al., 1991; Saheki et al., 1994), it might be that other RAS-RAF-MEK-ERK signaling inhibitors are better suited to treat NF1-associated cognitive deficits in human patients. This evidence concerns the gene NF1 and Cognitive impairment.